Aileron Story

<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:4em;'>AT</div>
ALRN -- USA Stock  

USD 1.17  0.04  3.31%

Aileron Therapeutics Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 46.03 Million. Tangible Asset Value is expected to rise to about 23.4 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (22.7 M). As many baby boomers are still indifferent towards healthcare space, it makes sense to outline Aileron Therapeutics. We will evaluate why recent Aileron Therapeutics price moves suggest a bounce in May. This post is to show some fundamental factors affecting Aileron Therapeutics' products and services. I will also disclose how it may impact the investing outlook for the firm in May.
Published over two weeks ago
View all stories for Aileron Therapeutics | View All Stories
Aileron Therapeutics (NASDAQ:ALRN) continues to rise
About 32.0% of Aileron Therapeutics shares are held by company insiders. Insiders ownership of Aileron Therapeutics refers to the amount of Aileron Therapeutics equity owned by Aileron officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Aileron, including its current ownership diagnostics.

Watch out for price decline

Please consider monitoring Aileron Therapeutics on a daily basis if you are holding a position in it. Aileron Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Aileron Therapeutics stock to be traded above the $1 level to remain listed. If Aileron Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Aileron Therapeutics's Liquidity

Aileron Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Aileron Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aileron Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Aileron Therapeutics's total debt and its cash.

How Aileron utilizes its cash?

To perform a cash flow analysis of Aileron Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Aileron Therapeutics is receiving and how much cash it distributes out in a given period. The Aileron Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Aileron Therapeutics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (22.09 Million)

Purchase by Satter Muneer A of 9000000 shares of Aileron Therapeutics

Legal trades by Aileron Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Aileron insider trading alert for perchase of common stock by Satter Muneer A, the corporate stakeholder, on 8th of January 2021. This event was filed by Aileron Therapeutics Inc with SEC on 2021-01-08. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Aileron Therapeutics retains a total of 90.21 Million outstanding shares. Aileron Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
Retail Investors54.01

Our take on today Aileron Therapeutics rise

The maximum drawdown is down to 51.56 as of today. Aileron Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Aileron Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Aileron Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Aileron Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Aileron Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Whereas few other entities under the biotechnology industry are still a bit expensive, Aileron Therapeutics may offer a potential longer-term growth to institutional investors. The inconsistency in the assessment between current Aileron valuation and our trade advice on Aileron Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aileron Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aileron Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to